Established to support Canadian Oncology Research
- Ozmosis is a Canadian social enterprise CRO investing profits into research
- Spin out of Drug Development Program from Princess Margaret Cancer Centre
Our Executive Team
Our Executive Team has extensive experience designing and managing oncology clinical trials
Board of Directors
Our Board comprises a collection of world leaders in oncology research and provides leadership and scientific expertise
Dr Amit Oza is a Senior Staff Physician and Professor of Medicine at Princess Margaret Cancer Centre, University of Toronto. He is a Scientist with the Ontario Cancer Institute and cross-appointed to the Department of Obstetrics and Gynecology at the University of Toronto. He graduated from St. Bartholomew’s Hospital, University of London (UK), in 1983 and completed his internal medicine and medical oncology training in the UK. He completed Clinical Research Fellowships at St. Bartholomew’s Hospital/Imperial Cancer Research Fund, London (UK), Princess Margaret Cancer Centre, Toronto and at the Netherlands Cancer Institute, Amsterdam. His postgraduate research thesis was on Molecular Epidemiology of Hodgkin’s Disease. He is a Fellow of the Royal College of Physicians of London and Canada.
Dr Oza has been the principal investigator and co-investigator in phase I, II, and III trials for gynaecological cancer and advanced colorectal malignancies. His research interests are focused on the development, assessment, and validation of novel therapeutic strategies for cancer including molecular targeted therapies. Many of these studies also incorporate novel endpoints and translational research which is developed in close relationship with scientists and pathologists from the OCI/PMCC.
Dr Oza has been the recipient of various awards such as the University of Toronto Award for Teaching Excellence for the Medical Oncology Training Program, the Hasselback Award for Teaching Excellence from Princess Margaret Hospital and many others. He has also been principal and co-author of numerous publications in major peer-reviewed journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs and Clinical Cancer Research.
He is currently Medical Director of the Clinical Cancer Research Unit at Princess Margaret Cancer Centre and Co-Director of the Robert and Maggie Bras and Family Drug Development Program at Princess Margaret Cancer Centre. This is the largest new drug development program in Canada and the only centre outside the US to have a contract with the NIH for Early Phase Therapeutic studies. He is also Co-Chair of the Gynecology Site Committee of the NCIC Clinical Trials Group and represents NCIC CTG at the Gynecologic Cancer InterGroup.
Ms Degendorfer is Chief Operating Officer at Ozmosis Research, a social enterprise company that manages oncology clinical trials both nationally and internationally. She has been an integral part of the company from inception and worked with Dr Oza to start Ozmosis Research in 2005.
Ms Degendorfer is also the Program Director for the Cancer Clinical Research Unit (CCRU) at the Princess Margaret Cancer Centre. As Program Director since 2009, Ms Degendorfer guides the operations and strategic direction of the CCRU and clinical research across Princess Margaret.
After graduating with a Master’s Degree from the University of Toronto, Ms Degendorfer began her career at Princess Margaret in 1987. She was recruited to the Drug Development Program in 2001, where she was appointed Manager of the Robert & Maggie Bras and Family New Drug Development Program (DDP) helping build the program into the largest cancer drug development program in Canada. The DDP held an N01 contract through the NCI for many years and is an ETCTN member. Ms Degendorfer has worked extensively with CTEP trials and managed a consortium of sites as part of the N01.
She has been an expert consultant for academic cancer centres in Canada and abroad. Working with a variety of sponsors including pharmaceutical companies, biotechnology companies and the National Cancer Institute in both the United States and Canada has given Ms Degendorfer a wide breadth of experience in clinical trials management.
Mary Gospodarowicz is the Medical Director of the Cancer Program at Princess Margaret Cancer Centre and University Health Network and the Regional Vice President of Cancer Care Ontario. She is also the Professor and Chair of the Department of Radiation Oncology at the University of Toronto and Chief of the Radiation Medicine Program at Princess Margaret Cancer Centre.
She received her MD degree from the University of Toronto and holds speciality certifications in internal medicine, medical oncology, and radiation oncology. She is an honorary Fellow of the Royal College of Radiologists in the United Kingdom, an honorary member of the European Society of Therapeutic Radiology and Oncology (ESTRO), a Fellow of the American Society of Therapeutic Radiology and Oncology (ASTRO) and past president of the Canadian Association of Radiation Oncologists (CARO).
She is engaged in an active clinical practice of radiation oncology treating patients with malignant lymphomas and genitourinary cancers. Her research interests include clinical trials evaluating the role of radiation therapy in lymphomas, prostate cancer, and testis cancer. Currently, her interests are in developing and implementing image-guided precision radiotherapy, late effects research, survivorship programs and research. She has a major interest in cancer staging and prognostic factor classification. She currently co-chairs the TNM Prognostic Factors Project for the International Union Against Cancer (UICC). Mary Gospodarowicz has served on various provincial, national and international committees. She is a member of the Board of Directors of UICC and the Chair of its Membership Committee. UICC is an international non-governmental organization dedicated to the global control of cancer.
Dr Piyush Patel is the co-founder of Allied Research International(ARI). Dr Patel has grown the organization into a leading provider of early-stage, bioanalytical and niche late-stage clinical research services to the life sciences industry. He has refined existing clinical models of allergy research to establish new ways of studying these areas. In 2006, ARI expanded to the U.S. with a major research unit in Miami. In 2007, Cetero Research acquired ARI, making it part of a wider family of clinical and bioanalytical research specialists.
He has designed numerous Phase I/Proof of concept studies and has been involved as principal investigator in more than 300 clinical trials. His Board Certification in Clinical Immunology and Allergy, as well as his in-depth experience in respiratory and immunology clinical research has led to his active participation in various appointments. These include Advisory Board Member (Allergy & Asthma) in several large Pharmaceutical companies, participation in FDA’s Pharmaceutical Sciences Advisory Committee, as well as his role as Chairman of the AAPS Nasal Drug Delivery Focus Group. A true leader in clinical research, Dr Piyush Patel was awarded the Ernst & Young Entrepreneur Of The Year Award for Canada in 2008.
Dr Paige earned a PhD in Immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979. He became a Member of the Basel Institute for Immunology in Switzerland where he worked from 1980-1987 before joining the Ontario Cancer Institute as a Senior Scientist in 1987. In 1990, Dr Paige became the founding Director of the Arthritis and Autoimmunity Research Centre as well as Director of Research at The Wellesley Hospital. In 1998, Dr Paige returned to the Ontario Cancer Institute to assume the role of Vice-President, Research and, subsequently, he assumed his current position of Vice-President, Research at the University Health Network which is comprised of the Toronto General, Toronto Western and Princess Margaret Cancer Centre. Dr Paige is a Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto.
His continuing research interest is in the development of the immune system and in training the immune system to recognize cancer cells. He has served on the Research Advisory Boards of both the National Cancer Institute and the Arthritis Society of Canada. He is Chairman of BioDiscovery Toronto, a consortium of 12 Toronto based hospitals and universities engaged in the commercialization of research discoveries. He also serves on the Boards of the Terry Fox Research Institute, Ontario Institute for Cancer Research, and the Council of Ontario Research Directors. He is the co-Director of the Shanghai-Toronto Institute for Health Science (STI), a partnership between the Shanghai Institute of Health Sciences, Shanghai Institute of Organic Chemistry, and the University Health Network.
Our Value Proposition
Solid tumour, malignant hematology, and clinical trial design
Knowledgeable and committed team working collaboratively with sponsors to successfully operationalize and execute their trials
Strong relationships with sites across North America, Europe, and Australia
A flexible and adaptable organization that can help to expedite trial initiation and patient recruitment